Keyword: Teva Pharmaceutical
Teva has long called Pennsylvania its U.S. home base, but New Jersey is trying to woo it away with $40M in tax incentives.
In the tardive dyskinesia market, doctors initially preferred Neurocrine’s Ingrezza over Teva’s Austedo. But that edge is weakening, one analyst says.
Pharma authorized tens of billions of dollars' worth of share buybacks before or shortly after tax reform, and that irked an industry veteran.
Even as major drug pricing scandals such as EpiPen gained national attention, routine price hikes on another drug largely went unnoticed.
After learning Aimovig's official price, ICER revised its work to conclude the migraine prevention drug is cost-effective when other options fail.
Celltrion says it has made enough progress fixing issues at its plant cited by the FDA and has resubmitted its application for its version of Rituxan.
Teva’s rebrand is taking another step forward with the debut of Life Effects, a website centered on patients living with different chronic conditions.
Joining other drug companies announcing slim-down efforts in recent months, Astellas is shedding 600 jobs in Japan in R&D and sales and marketing.
Doctors who got free meals, speaking fees and other payments from drugmakers also prescribed more opioids, a new analysis found.
In a new twist on the good news/bad news paradigm, the FDA has informed Perrigo to expect a CRL for its copy of Teva’s popular ProAir inhaler.